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O B J E C T I V E S We aimed to investigate whether early thrombus formation can be visualized with
in vivo magnetic resonance imaging (MRI) by the use of a novel bimodal 2-antiplasmin–based contrast
agent (CA).
B A C KG ROUND Thrombus formation plays a central role in several vascular diseases. During the early
phases of thrombus formation, activated factor XIII (FXIIIa) covalently cross-links 2-antiplasmin to ﬁbrin,
indicating the potential of 2-antiplasmin–based CAs in the detection of early thrombus formation.
METHOD S A bimodal CA was synthesized by coupling gadolinium-diethylene triamine pentaacetic acid
and rhodamine to an 2-antiplasmin–based peptide. For the control CA, a glutamine residue essential for
cross-linking was replaced by alanine. In vitro-generated thrombi were exposed to both CAs and imaged by
MRI and 2-photon laser-scanning microscopy. Immunohistochemistry was performed on human pulmonary
thromboemboli sections to determine the presence of 2-antiplasmin and FXIII in different thrombus
remodeling phases. In vivo feasibility of the CA in detecting early thrombus formation speciﬁcally was
investigated with MRI.
R E S U L T S In vitro–generated thrombi exposed to the 2-antiplasmin–based CA showed hyperintense
magnetic resonance signal intensities at the thrombus edge. No hyperintense signal was observed when we
used the 2-antiplasmin–based CA in the presence of FXIII inhibitor dansylcadaverine nor when we used the
control CA. Two-photon laser-scanning microscopy demonstrated that the 2-antiplasmin–based CA bound
to ﬁbrin. Immunohistochemistry demonstrated substantial 2-antiplasmin staining in fresh compared with
lytic and organized thrombi. The administration of CA in vivo within seconds after inducing thrombus
formation increased contrast-to-noise ratios (CNRs 2.28  0.39, n6) at the site of thrombus formation
compared with the control CA (CNRs 0.14  0.55, p  0.003, n  6) and 2-antiplasmin–based CA
administration 24 to 48 h after thrombus formation (CNRs 0.11  0.23, p  0.006, n  6).
CONC L U S I O N S A bimodal CA was developed, characterized, and validated. Our results showed that
this bimodal CA enabled noninvasive in vivo magnetic resonance visualization of early thrombus formation.
(J Am Coll Cardiol Img 2009;2:987–96) © 2009 by the American College of Cardiology Foundation
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988hrombotic complications such as myocar-
dial infarction, stroke, deep venous thrombo-
sis, and pulmonary thromboembolism are ma-
jor causes of morbidity and mortality (1,2).
he resistance of thrombi to fibrinolytic therapy
ncreases with the age of the thrombus (3), and
brinolytic agents can induce severe complications
uch as bleeding (4,5). It is therefore necessary to
ccurately diagnose early thrombus formation be-
ause it may improve the selection of patients that
ill benefit from fibrinolytic therapy. Currently, the
oninvasive detection of early thrombus formation
s a major problem in clinical practice. Several
specific contrast agents (CAs) have been
developed to visualize thrombi by the use
of molecular imaging techniques (6–8).
Fibrin has frequently been used as a target
for in vivo thrombus visualization with
various magnetic resonance imaging (MRI)
CAs, such as fibrin-targeted perfluorocar-
bon nanoparticles (9) and fibrin-specific
peptide-based CAs (10 –17). Recently,
initial results of a human study in which
the authors used a fibrin-specific peptide-
based CA (EP-2104R) were published,
suggesting selective molecular MRI of
thrombi (18). Nonetheless, these CAs
have low sensitivity for the estimation of
thrombus age.
In this study, we searched for other
coagulation factors that could be used as
targets for thrombus imaging. We focused
on activated factor XIII (FXIIIa) because
it cross-links fibrin chains and covalently
cross-links 2-antiplasmin (2-AP) to fi-
brin (19). In this latter process, the glu-
tamine (Gln2) substrate in the N-terminal
domain of 2-AP is the primary substrate
site for FXIIIa (20). Robinson et al. (21)
have shown that the catalytic ability
of FXIIIa in cross-linking 2-AP into
ormed thrombi declines with a short half-life.
herefore, an 2-AP–based CA might enable spe-
ific visualization of early thrombus formation.
Recently, a near-infrared fluorescent (NIRF)
robe (A15) and a MRI CA (A14), both based on
2-AP, enabled the visualization of in vitro–formed
BSIK) program entitled Molecular Imaging of Ischemic Heart Disease (p
oundation, grant number 2002.B033. Drs. Daemen and Heeneman
etwork (grant LSHM-CT-2003-503254). Drs. Herı´as and Prinzen con
dal
ast
l
o
d
assanuscript received August 21, 2008; revised manuscript received March 11hrombi with the use of NIRF and ex vivo MRI
22). Subsequently, in vivo detection of FXIII
ctivity was achieved by intravital fluorescence mi-
roscopy using the A15 probe (23,24). However,
ranslation of this probe to human studies in the
ear future is unlikely because of the limited pene-
ration depth of NIRF microscopy. Noninvasive
hrombus visualization with the use of imaging mo-
alities such as MRI may overcome this limitation.
In the present study, we analyzed the presence of
XIII and 2-AP in fresh, lytic, and organized
uman pulmonary thromboemboli by the use of
mmunohistochemistry. Subsequently, we investi-
ated whether early thrombus formation can be
isualized in vitro and in vivo with MRI by using a
imodal 2-AP–based CA. Additionally, TPLSM
as used to investigate whether the 2-AP–based
A co-localizes with the fibrin polymers.
A T E R I A L S A N D M E T H O D S
ynthesis of the CAs. An 2-AP–based peptide se-
uence (GNQEQVSPLTLL) that binds covalently
o fibrin (21,23) was synthesized by the use of
ertbutyloxycarbonyl solid-phase peptide synthesis
25). The peptide was bimodally labeled with rho-
amine and a diethylene triamine pentaacetic acid
DTPA)-chelate (specific bimodal 2-antiplasmin–
ased contrast agent [Bi-2AP-CA]) by cross-
inking maleimide-DTPA (26) and succinimidyl-
hodamine (Invitrogen, Molecular Probes, Breda,
he Netherlands) to an additional C-terminal KW
ipeptide branched at the lysine -amino group
ith a cysteine. A control CA (Bi-con-CA) was
btained by replacing a glutamine residue essential
or cross-linking by alanine (Q3¡A3) to prevent
inding to fibrin (Fig. 1). Bi-2AP-CA and
i-con-CA were characterized by matrix-assisted
aser desorption/ionization mass spectrometry
MALDI-MS). Gadolinium chloride was added in
0.9:1 molar ratio, after which no MALDI spec-
rum was observed because of poor ionization.
ontrast agent validation. For r1 relaxivity measure-
ents, the gadolinium-labeled peptides were dis-
olved (concentrations ranging from 25 to 150
mol/l) in phosphate-buffered saline solution
PBS). Solutions were imaged at room temperature
ct number BSIK03033) and by the Dutch Heart
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989ith a 1.5-T MR scanner (MR Intera, Philips
ealthcare, Best, the Netherlands) with the use of
commercially available head coil and a 7.0-T
ruker Biospec scanner (Bruker Biospin GmbH,
ttlingen, Germany) by the use of a 154-mm
iameter quadrature transmit-receive radio-frequency
oil. T1 relaxation times were obtained by the use of
nversion recovery sequences with different inver-
ion times (TI), ranging from 50 to 5,000 ms.
dditional parameters were as follows: repetition
ime (TR), 7,500 ms; echo time (TE), 14 ms
1.5-T) or 8.4 ms (7.0-T); slice thickness, 3 mm;
umber of signal averages (NSA), 1; and in-plane
esolution, 0.55  0.55 mm. Gadolinium content
as determined by the use of inductively coupled
lasma mass spectrometry. The effect of Bi-
2AP-CA on thrombus formation was determined
ith a thrombin generation assay using platelet
oor plasma with different concentrations (0, 10,
0, and 40 mol/l) of Bi-2AP-CA.
n vitro thrombus imaging. Human blood was ob-
ained by venous puncture from a healthy volunteer
nd collected in vacutainer tubes containing triso-
ium citrate (BD Vacutainer Systems, Preanalytical
olutions, Plymouth, United Kingdom). Murine
lood was obtained by right ventricle puncture.
uman and murine thrombi were allowed to form
Figure 1. Structure of the Bimodal 2-Antiplasmin–Based Contr
Schematic representation of the 2-AP–based peptide that is bimod
acid-chelate (Bi-2AP-CA) and the corresponding mass spectra. Mat
molecular mass of 2,832.92 g/mol for the Bi-2AP-CA. Substitution o
(Bi-con-CA).uring 90 min at 37°C in the presence of 30 l of p.5 mg/ml Oregon Green 488-labeled fibrinogen
Invitrogen, Molecular Probes, Breda, the Nether-
ands). Thereafter, thrombi were incubated with
50 mol/l Bi-2AP-CA or Bi-con-CA for 90 min
t 37°C, followed by extensive washing with PBS.
o determine the effect of FXIIIa on thrombus
isualization, a human thrombus was formed and
xposed to Bi-2AP-CA in the presence of dan-
ylcadaverine (final concentration 2 mmol/l; Fluka
hemie AG, Buchs, Switzerland) because dan-
ylcadaverine is a competitive substrate for transglu-
aminases such as FXIII (27).
Visualization with TPLSM was performed as
reviously described (28). In brief, a BioRad
100MP (Hemel Hampstead, United Kingdom)
as used in TPLSM mode. Fluorescence was de-
ected by 3 photomultipliers. Filter settings were as
ollows: 420 to 470 nm (blue), 510 to 540 nm
green, fibrin network), and 570 to 590 nm (red,
hodamine detection of the CAs).
After TPLSM and approximately 4 h after CA
ncubation, thrombi were embedded in 2% agarose
el and imaged at 1.5-T by the use of a commer-
ially available 47-mm diameter surface coil (Philips
ealthcare, Best, the Netherlands). Images were
cquired with a T1-weighted inversion recovery
urbo spin echo sequence with the following scan-
Agent
labeled with rhodamine and a diethylene triamine pentaacetic
ssisted laser desorption/ionization mass spectrometry shows a
ly one amino acid (Q3¡A3) results in a bimodal control CAast
ally
rix-a
f onarameters: TR/TE/TI, 1,580/13/546 ms; echo
t
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990rain length, 6; NSA, 16; slice thickness, 1.5 mm;
eld of view, 40  40 mm; and matrix size,
92  192.
hrombus age classiﬁcation. To assess whether
XIII and 2-AP can be seen as markers for early
hrombus formation, tissue sections with pulmo-
ary thromboemboli were evaluated by immuno-
istochemistry. Twenty-two paraffin-embedded
locks (15 from 8 autopsy patients and 7 from 3
ung biopsy tissues) containing pulmonary throm-
oemboli were used to analyze FXIII and 2-AP
resence. All tissues were obtained from the Maas-
richt Pathology Tissue Collection. Collection,
torage, and use of tissue and patient data were
erformed in agreement with the “Code for Proper
econdary Use of Human Tissue in the Netherlands.”
Immunohistochemistry was performed with con-
entional methods. In brief, mouse monoclonal
ntihuman FXIII alpha subunit (1:300; clone AC-
A1, Lab Vision, Fremont, California), rabbit-
ntihuman 2-AP polyclonal (1:200; Biogenesis-
orphoSys AG, Martinsried/Munich, Germany),
nd mouse monoclonal antihuman fibrin II beta
hain (1:100; clone T2G1, Accurate Chemical,
estbury, New York) were used as primary anti-
odies. For the negative controls, no primary anti-
ody was used. Visualization was achieved with
ectastain red (alkaline phosphatase substrate kit I,
ector Laboratories, Burlingame, California).
Thrombi were classified into fresh (1 day;
ayered patterns of platelets, fibrin, erythrocytes,
nd intact granulocytes), lytic (1 to 5 days; areas of
olliquation necrosis and karyorrhexis of granulo-
ytes), organizing thrombi (5 days; ingrowth of
mooth muscle cells with or without deposition
f connective tissue and capillary vessel ingrowth),
r in thrombi containing more than one of these
ge classifications (29). Percentages of thrombi
ositive for FXIII, 2-AP, and fibrin staining were
etermined for the various thrombus age classifica-
ions. The degree of staining was scored for each
hrombus age classification separately in no staining
score 0), slightly stained (score 1), moderately
tained (score 2), and strongly stained (score 3) (by
.H., intraobserver variability 10%).
learance and biodistribution. All animal experi-
ents were approved by the local ethical review
ommittee. Mice were anesthetized by inhalation of
ir with 2% isoflurane inhalation gas. Half-life of
i-2AP-CA (n  3) and Bi-con-CA (n  3) was
etermined by collecting blood samples before and
t different time-points (1, 10, 15, 30, 60, and 90
in) after contrast administration (dose 5.0 (mol/kg body weight). With the use of TPLSM,
ean fluorescence of the red channel was deter-
ined in all blood samples. Exponential fitting was
sed for half-life determination (GraphPad Prism
.0, La Jolla, California). After blood collection,
ice were sacrificed by an excess of pentobarbital.
e determined the biodistribution of both CAs
ith TPLSM by studying CA uptake in excised
iver, spleen, kidney, heart, lung, and intestine.
ilter settings were as follows: 500 nm (blue), 500
o 560 nm (green) and 560 to 610 nm (red,
hodamine detection of the CAs).
n vivo thrombus imaging. The right carotid artery
as exposed by separating the sternocleidomastoid
uscle from the trachea. Thrombus formation was
nduced by applying a strip of filter paper soaked in
0% ferric chloride (FeCl3) on the carotid artery.
fter 5 min, the filter paper was removed, and the
arotid artery was washed with PBS. Within sec-
nds after FeCl3-induced thrombus formation, 5.0
mol/kg body weight Bi-2AP-CA (n  6) or
i-con-CA (n  6) was administered intrave-
ously. In 6 other mice, Bi-2AP-CA was admin-
stered 24 to 48 h after FeCl3-induced thrombus
ormation.
MRI was performed at 7.0-T by the use of a
5-mm diameter quadrature transmit-receive ra-
iofrequency coil (Bruker Biospin GmbH, Ettlin-
en, Germany). After scout scans, sagittal carotid
R images were obtained approximately 90 min
fter CA administration by the use of a rapid
cquisition with relaxation enhancement inversion
ecovery pulse sequence. Parameters were as fol-
ows: TR/TE/TI, 7,500/8.9/1,654 ms; 21 to 25
lices; slice thickness, 0.25 mm; interslice distance,
.3 to 0.35 mm; NSA, 2; rare partitions, 4; field of
iew, 30  30 mm; matrix size, 312  312.
dditionally, after Bi-2AP-CA administration
ithin seconds after thrombus formation, repeated
R measurements were performed (50, 65, 85,
00, 115, and 130 min, n  2).
For TPLSM, carotid arteries (n  4 for each
roup) were excised and mounted into a home-built
erfusion chamber (IDEE BV, Maastricht, the
etherlands) and immersed in Hanks balanced salt
olution while maintaining 60 to 80 mm Hg trans-
ural pressure (28). Syto 13 (Invitrogen, Eugene,
regon) was added (final concentration 2.5 mol/l)
o visualize nucleic acids. Filter settings were as
ollows: 420 to 470 nm (blue), 510 to 530 nm
green, nucleic acid staining), and 560 to 610 nm
red, rhodamine detection of the CAs).
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991Magnetic resonance contrast-to-noise ratios
CNRs) were calculated by dividing the difference
etween the mean MR signal intensities from a
egion of interest positioned in the thrombus and
hat in neighboring muscle tissue by the noise
easured in air. Noise values were corrected for
agnitude effects by the Rayleigh factor. Regions of
nterest were drawn in ParaVision 4.0 (Bruker
iospin GmbH, Ettlingen, Germany).
tatistics. Data are presented as mean  standard
rror. Statistical analyses were performed on the
istology scores using the Mann-Whitney U test.
or in vivo measurements the one-way analysis of
ariance test was used. Because of Bonferroni cor-
ection for multiple group comparison, differences
ith a p value 0.025 were considered significant.
E S U L T S
ynthesis of the CAs. The use of MALDI-MS
howed a molecular mass for Bi-2AP-CA of
832.9 g/mol, in agreement with the theoretical
verage mass of 2893.1 g/mol without Gd3 bound
Fig. 1). The Bi-con-CA with a Q3 to A mutation
ad a molecular mass of 2775.4 g/mol, correspond-
ng to the theoretical average mass of 2776.1 g/mol
ithout Gd3 attached (data not shown).
ontrast agent validation. The r1 relaxation times of
he Bi-2AP-CA at 1.5- and 7.0-T were 5.6  0.4
M1s1 and 3.0  0.3 mM1s1, respectively.
he r1 relaxation times obtained for Bi-con-CA
ere 6.50.5 mM1s1 (1.5-T) and 3.3  0.2
M1s1 (7.0-T).
For all Bi-2AP-CA concentrations (0, 10, 20,
nd 40 mol/l) the endogenous thrombin poten-
ials were comparable (708, 742, 733, and 717
mol/l · min, respectively). Additionally, no effects
f Bi-2AP-CA on thrombin peak heights or lag
imes of thrombin generation were observed. These
esults indicate that Bi-2AP-CA did not interfere
ith thrombin generation and subsequent throm-
us formation.
n vitro thrombus imaging. The use of TPLSM
howed costaining of the rhodamine-labeled Bi-
2AP-CA (red) and the OG488-labeled fibrin
etwork (green), resulting in yellow areas of colo-
alization, indicating binding of Bi-2AP-CA to
brin in human and murine thrombi (Figs. 2B and
H). In contrast, the control agent Bi-con-CA
howed limited labeling and colocalization with the
brin network (Figs. 2D and 2J). Hyperintense
RI signals were found at the edge of thrombincubated with Bi-2AP-CA (Figs. 2A and 2G),Figure 2. In Vitro Results
Results of TPLSM and MRI for human (A to F) and murine (G to J) thrombi
incubated with the bimodal 2-AP–based contrast agent (Bi-2AP-CA) (A, B,
E to H) and the bimodal control CA (Bi-con-CA) (C, D, I to J). For TPLSM,
red color originates from the rhodamine-labeled CAs. Green color indicates
the ﬁbrin network due to use of ﬁbrinogen–Oregon green 488. Yellow color
illustrates colocalization of red and green. Hyperintense MR signals were
found at the edge of thrombi incubated with Bi-2AP-CA (A, G). Lower MR
signal intensities were found at the edge of a thrombus exposed to dan-
sylcadaverine and Bi-2AP-CA (E). MRI  magnetic resonance imaging;
TPLSM  2-photon laser-scanning microscopy.
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992hich were absent when Bi-con-CA was used
Figs. 2C and 2I). FXIIIa inhibition by dansylca-
averine decreased binding and co-localization of
i-2AP-CA with fibrin, thereby lowering the MR
ignal intensity at the edge of a human thrombus
xposed to Bi-2AP-CA (Figs. 2E and 2F). This
nding confirms that FXIII presence is needed for
i-2AP-CA binding to fibrin.
Immunohistochemistry staining for FXIII and
2-AP on a human thrombus formed during 3 h
Figure 3. Immunohistochemical Stainings of Thrombi
(A) Factor XIII staining. (B) 2-Antiplasmin staining. Positive
staining is depicted in red/pink color. Factor XIII staining (scat-
tered spots) was present throughout the whole thrombus while
2-antiplasmin staining was mainly depicted at the edge of the
thrombus (arrows). Bars  50 m.
and Scores of 2-Antiplasmin, Factor XIII, and Fibrin Stainings in
2-Antiplasmin Fa
Positive
Staining (%) Mean Score  SE
Positive
Staining (%)
95 1.4 0.1 * 92
29 0.3 0.2 * 75
20 0.2 0.1 31howed that FXIII was present throughout the
hrombus (Fig. 3A), whereas 2-AP was strongly
xpressed at the edge (Fig. 3B). This finding is in
ine with the increased MR signal intensities at the
dge of thrombi exposed to Bi-2AP-CA.
hrombus age classiﬁcation. We evaluated 44
hrombi for FXIII, 38 for 2-AP, and 47 for fibrin
nd categorized them in fresh, lytic, or organized.
igh percentages of positive fibrin staining were
ound in all categories, whereas positive 2-AP and
XIII staining was mainly present in fresh thrombi
ollowed by lytic and organized thrombi. Addition-
lly, mean 2-AP score was significantly greater in
resh thrombi compared with lytic and organized
hrombi, and mean FXIII score was significantly
reater in fresh compared with organized thrombi
hile no significant difference was found between
resh and lytic thrombi. Mean fibrin score was
elatively high in all thrombus age classifications
Table 1). Additionally, FXIII was expressed in
nflammatory cells (mainly macrophages), repre-
enting the cellular component of FXIII. A typical
xample of a thrombus containing fresh and orga-
ized components is shown in Figure 4.
learance and biodistribution. Both CAs were rap-
dly cleared from the blood. Circulation half-lives of
i-2AP-CA and Bi-con-CA were 14.1 8.4 min
nd 16.3  4.0 min, respectively. The use of
PLSM on excised organs showed that both CAs
ere mainly cleared through the kidneys, whereas
imited CA was found in other organs (Fig. 5),
ndicating that there is no or limited accumulation
f the CAs on organ level.
n vivo thrombus imaging. Clear hyperintense sig-
als from early thrombus formation were observed
ith in vivo MRI (CNR 2.29  0.39) when
i-2AP-CA was administered immediately after
eCl3-induced thrombus formation. No hyperin-
ense MR signals were found when the control
gent (Bi-con-CA) was used for fresh thrombus
isualization (CNR 0.14  0.55, p  0.003) nor
hen Bi-2AP-CA was used for the visualization
f 24- to 48-h–old thrombi (CNR 0.11  0.23,
ng Emboli Tissue Sections
r XIII Fibrin
Mean Score  SE
Positive
Staining (%) Mean Score  SE
1.5 0.1 100 2.1 0.1
0.8 0.3 * 83 2.0 0.4
0.3 0.1 92 1.9 0.2Table 1. Percentages Lu
cto
Thrombus Age
Fresh (1 day)
Lytic (1–5 days)
Organized (5 days)
*Signiﬁcantly different.
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993 0.006) (Figs. 6A to 6D). Additionally, CNR
atios as a function of time after Bi-2AP-CA
dministration (50, 65, 85, 100, 115, and 130 min)
ere comparable (2.65 0.11, 2.43 0.06, 2.51
.15, 2.43  0.37, 2.24  0.21, and 2.01  0.44,
espectively).
The use of TPLSM on excised carotid arteries
onfirmed Bi-2AP-CA presence in the thrombi
ormed in the lumen of the FeCl3-treated artery
hen Bi-2AP-CA was administered within sec-
nds after thrombus formation (Fig. 6E). Limited
uorescence was found by the use of Bi-con-CA
Fig. 6F) or when Bi-2AP-CA was administered
4 to 48 h after FeCl3-induced thrombus formation
Fig. 6G). Occasionally, fluorescence was found in
he medial layer (predominantly smooth muscle
ells) of vessels that were treated with FeCl3 24 to
Figure 4. Pulmonary Thromboemboli Sections
Middle panels demonstrate an overview of thromboemboli, from t
stained for ﬁbrin, factor XIII, and 2-antiplasmin. Bars  300 m. Le
part of the thrombo-emboli. In the enlarged FXIII stained area clear
enlargements of boxed areas indicating a fresh segment (arrows). B8 h before imaging. No fluorescence was detected pn the nontreated contralateral carotid arteries. His-
ology confirmed presence of thrombi in all FeCl3-
reated carotid arteries.
I S C U S S I O N
ecause 2-AP covalently cross-links to fibrin dur-
ng the early phases of thrombus formation, 2-
P–based CAs might enable the noninvasive de-
ection of early thrombus formation. We
emonstrated that the 2-AP–based CA enabled
RI and TPLSM of in vitro–generated thrombi
nd that FXIII presence is required for binding of
he 2-AP–based CA to fibrin. Additionally, we
howed that 2-AP and FXIII are predominantly
resent in fresh compared with lytic and organized
uman pulmonary thromboemboli, indicating the
o bottom: hematoxylin and eosin stained, immunohistochemically
anels show enlargements of boxed areas indicating an organized
ular FXIII staining is visable. Bars  50 m. Right panels show
 50 m.op t
ft p
cellotential of 2-AP–based CAs in detecting early
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994hrombus formation. Subsequently, we demon-
trated that the 2-AP–based CA enabled the in
ivo visualization of early thrombus formation with
RI. The use of TPLSM confirmed specific bind-
ng of the 2-AP–based CA to fibrin.
Previously, 2-AP–based peptides labeled with
ither Alexa680 (A15) or gadolinium (A14) were
sed in vitro for visualization with NIRF micros-
opy and MRI. Both probes were tested for their
bility to visualize murine (22) and human thrombi
23). Additionally, it was shown that 2-AP–based
eptides bind covalently to fibrin (21,23), indicating
Figure 5. Clearance and Kidney Uptake of the Bi-2AP-CA and B
Relative ﬂuorescence measured in blood samples decreases with tim
8.4 min and 16.3  4.0 min for Bi-2AP-CA and Bi-con-CA respectiv
red indicates bimodal CA in kidney tubuli. CA  constrast agent.
Figure 6. In Vivo and Ex Vivo Results
In vivo MRI (A to C) and ex vivo TPLSM results (E to G) of early throm
injection of the bimodal 2-antiplasmin–based CA (Bi-2AP-CA) (A, C,
noise ratios (CNRs) are increased in the early phases of thrombus form
Bimodal CA, and green indicates nuclear stain. Lumen is located betw
bus. Elongated cells are smooth muscle cells (orange arrows) and endothehat the Kd value approaches 0. These findings were
onfirmed by the present study because the addition
f contrast 90 min after the initiation of thrombus
ormation resulted in a hyperintense MR signal at
he edge of human and murine blood-derived
hrombi.
In previous murine studies, intravital fluorescence
icroscopy enabled visualization of carotid (23) and
erebral (24) thrombi by use of the A15 probe. This
robe proved to be specific for the early phases of
hrombus formation (23). Nevertheless, because of the
imited penetration depth of NIRF microscopy it is
n-CA
fter contrast administration (A). Half-lives of the CAs are 14.1 
CAs are mainly cleared through the kidney (B and C). In B and C,
formation and 24- to 48-h thrombi in murine carotid arteries after
d G) and the bimodal control CA (Bi-con-CA) (B, F). Contrast-to-
after Bi-2AP-CA administration (D). In E to G, red indicates
dotted lines. Blue arrows indicate leukocytes trapped in the throm-i-co
e a
ely.bus
E, an
ation
eenlial cells (red arrow). Abbreviations as in Figures 2 and 5.
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995nlikely that this probe can be used for human
pplications. Our 2-AP–based CA enabled in vivo
isualization of early thrombus formation with non-
nvasive MRI. In our MRI study a greater CA dose
as used compared with the NIRF studies (23,24).
owever, the present dose (5 mol/kg) is still low for
RI. Biological amplification due to the abundance
f fibrin and r1 relaxivity increase upon binding may
xplain the observed signal enhancement achieved
ith this low dose.
Other fibrin-targeted imaging studies used compa-
able CA concentrations (10–18). Fibrin-targeted
erfluorocarbon nanoparticles (9), EP-1242 (17), EP-
873 (16), and EP-2104R (10–15,18), have been
roven in their ability to visualize thrombi in different
nimal models with MRI. Recently, initial results
howed that EP-2104R allows in vivo MRI thrombus
maging in humans (18). Additionally, EP-2104R
emonstrated a time-dependent thrombus enhance-
ent, demonstrating a slow decrease in CNR during
n 8-week time period (12). However, because in-
reased CNRs were observed in all thrombi compared
ith precontrast imaging, it is unlikely that this CA
ould effectively discriminate between the early stages
f thrombus formation and organized thrombi. In the
resent study, we demonstrated that the 2-AP–
ased CA significantly increased CNRs during early
hrombus formation compared with 24- to 48-h–old
hrombi. Therefore, our bimodal 2-AP–based CA is
romising for the differentiation between the early
hases of thrombus formation and organized thrombi.
Immunohistochemistry showed presence of FXIII
n pulmonary thromboemboli, but cellular FXIII
taining also was observed. The cellular form of FXIII
onsists of a homodimer of A-subunits (19). We used
primary antibody addressed to the -chain of FXIII,
xplaining the cellular FXIII staining. The importance
f FXIII beyond its function in coagulation is still not
ell known. An in vivo study, in which an 111In-
abeled 2-AP–based CA was used to visualize FXIII
ctivity in myocardial healing, suggested that FXIII
lays a role in wound healing and tissue repair (30).
herefore, the fluorescence observed in the medial
ayer of some carotid arteries might be explained
y tissue repair 24 to 48 h after FeCl3 treatment.
bdAlla et al. (31) suggested that intracellular
XIIIa-mediated monocyte adhesion during the ath-
rosclerotic process.
Noninvasive assessment of early thrombus forma-
ion versus organized thrombi could be of major
linical relevance because specific detection of early
hrombus formation may improve selection of patients tligible for fibrinolytic therapy, thereby reducing seri-
us side effects.
tudy limitations. First, there is only a limited time
indow during which this 2-AP–based CA can be
sed for thrombus detection. Second, whether our
A is able to detect thrombi that are sensitive to
brinolytic therapy remains to be determined.
hird, to prove its clinical usefulness, it remains to
e established whether this 2-AP–based CA in-
ibits thrombolysis using state-of-the-art thrombo-
ytics. However, this CA only contains the part that
s responsible for binding of 2-AP, which on its
wn is insufficient to inhibit plasmin activity.
ourth, our CA binds covalently to fibrin, indicat-
ng that the Gd-complex stability is of major
mportance since free Gd3-ions can induce neph-
ogenic systemic fibrosis. The ionic-macrocylic
OTA-chelate is more stable than the used
TPA-chelate; therefore, minor chelate adjust-
ent will improve its stability and decrease the risk
f nephrogenic systemic fibrosis. Fifth, to perform
re- and post-contrast MRI within the same mouse
n the same exact position, anticoagulants are
eeded ensuring that the cannula placed for con-
rast administration will not become obstructed.
ince anticoagulants interfere with thrombus for-
ation, no pre-contrast images were obtained.
owever, the used control CA validated the in-
rease in CNR of thrombi exposed to the 2-AP–
ased CA. Finally, determination of the optimal
osage is still needed.
O N C L U S I O N S
ur bimodal 2-AP–based CA enabled specific,
oninvasive visualization of the early phases of throm-
us formation, whereas no hyperintense signal was
bserved in 24- to 48-h–old thrombi. Therefore, this
imodal 2-AP–based CA might be able to specifi-
ally select patients who are eligible for fibrinolytic
herapy.
cknowledgments
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